CD36 and neoplasm: For example, selecting patients whose tumour and immune microenvironment show high FAO dependence (via elevated CPT1A, ACAD, or CD36 expression) may maximise benefit while monitoring liver enzymes, lipid profiles, and T cell memory markers may enhance safety (225).